 Liudmila Kulik
Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Complement 3d | 14 | 2017 | 140 | 1.850 |
Why?
| | Immunoglobulin M | 17 | 2023 | 289 | 1.720 |
Why?
| | Antibodies, Monoclonal | 10 | 2023 | 1419 | 1.240 |
Why?
| | Complement C3d | 5 | 2023 | 67 | 1.080 |
Why?
| | B-Lymphocytes | 12 | 2017 | 849 | 0.780 |
Why?
| | Reperfusion Injury | 7 | 2021 | 277 | 0.750 |
Why?
| | Receptors, Complement 3b | 4 | 2020 | 82 | 0.750 |
Why?
| | Glutamic Acid | 1 | 2023 | 248 | 0.690 |
Why?
| | Complement Activation | 11 | 2020 | 407 | 0.640 |
Why?
| | Epitopes | 9 | 2023 | 476 | 0.640 |
Why?
| | Antigen-Antibody Complex | 1 | 2019 | 87 | 0.630 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2019 | 239 | 0.530 |
Why?
| | Immune System Diseases | 1 | 2015 | 40 | 0.450 |
Why?
| | Arthritis, Experimental | 5 | 2020 | 140 | 0.440 |
Why?
| | Kidney Glomerulus | 4 | 2021 | 119 | 0.440 |
Why?
| | Mice | 31 | 2023 | 17769 | 0.380 |
Why?
| | Autoantibodies | 7 | 2019 | 1454 | 0.380 |
Why?
| | Annexin A4 | 2 | 2015 | 6 | 0.340 |
Why?
| | Mice, Knockout | 15 | 2019 | 3014 | 0.340 |
Why?
| | Models, Immunological | 1 | 2011 | 101 | 0.340 |
Why?
| | Kidney Diseases | 3 | 2023 | 409 | 0.340 |
Why?
| | Antibody Formation | 4 | 2010 | 298 | 0.340 |
Why?
| | Animals | 36 | 2023 | 37151 | 0.330 |
Why?
| | Complement C3 | 7 | 2021 | 203 | 0.320 |
Why?
| | Glomerulonephritis | 2 | 2023 | 47 | 0.310 |
Why?
| | Mice, Inbred C57BL | 17 | 2020 | 5769 | 0.290 |
Why?
| | Immunity, Innate | 4 | 2015 | 826 | 0.290 |
Why?
| | Single-Chain Antibodies | 2 | 2020 | 17 | 0.280 |
Why?
| | Glomerulosclerosis, Focal Segmental | 2 | 2021 | 45 | 0.270 |
Why?
| | Antibodies | 2 | 2017 | 406 | 0.250 |
Why?
| | Complement System Proteins | 2 | 2021 | 321 | 0.240 |
Why?
| | Complement Factor H | 2 | 2018 | 79 | 0.240 |
Why?
| | Intestinal Mucosa | 1 | 2009 | 621 | 0.210 |
Why?
| | Cell Differentiation | 4 | 2007 | 1999 | 0.210 |
Why?
| | Sheep | 5 | 2015 | 853 | 0.210 |
Why?
| | Annexins | 1 | 2023 | 2 | 0.200 |
Why?
| | Racemethionine | 1 | 2023 | 3 | 0.200 |
Why?
| | Receptors, Antigen, B-Cell | 3 | 2011 | 132 | 0.200 |
Why?
| | Receptors, Complement | 3 | 2022 | 122 | 0.200 |
Why?
| | Immunity, Humoral | 2 | 2015 | 117 | 0.200 |
Why?
| | Complement C3b | 1 | 2023 | 34 | 0.200 |
Why?
| | Immunoglobulin G | 5 | 2023 | 901 | 0.200 |
Why?
| | Antibody Specificity | 4 | 2021 | 187 | 0.200 |
Why?
| | Protein Multimerization | 2 | 2021 | 195 | 0.200 |
Why?
| | Foot-and-Mouth Disease | 1 | 2022 | 1 | 0.190 |
Why?
| | Foot-and-Mouth Disease Virus | 1 | 2022 | 1 | 0.190 |
Why?
| | Antigens, CD19 | 2 | 2015 | 123 | 0.190 |
Why?
| | Methionine | 1 | 2023 | 163 | 0.190 |
Why?
| | Erythrocytes | 4 | 2015 | 710 | 0.190 |
Why?
| | B-Lymphocyte Subsets | 3 | 2010 | 77 | 0.180 |
Why?
| | Complement Pathway, Classical | 1 | 2021 | 20 | 0.180 |
Why?
| | Nephrosis, Lipoid | 1 | 2021 | 10 | 0.180 |
Why?
| | Nephrotic Syndrome | 1 | 2021 | 38 | 0.180 |
Why?
| | Lymphocyte Activation | 4 | 2021 | 1146 | 0.170 |
Why?
| | Cardiolipins | 1 | 2021 | 83 | 0.170 |
Why?
| | Transplants | 1 | 2021 | 39 | 0.170 |
Why?
| | Disease Models, Animal | 5 | 2019 | 4309 | 0.170 |
Why?
| | Synoviocytes | 1 | 2020 | 17 | 0.170 |
Why?
| | Autoimmunity | 3 | 2019 | 899 | 0.170 |
Why?
| | Protein Processing, Post-Translational | 1 | 2023 | 464 | 0.160 |
Why?
| | Mice, Inbred MRL lpr | 1 | 2019 | 38 | 0.160 |
Why?
| | Mice, Transgenic | 7 | 2011 | 2166 | 0.160 |
Why?
| | Complement Inactivating Agents | 2 | 2021 | 62 | 0.160 |
Why?
| | Joints | 1 | 2020 | 105 | 0.160 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 10 | 0.160 |
Why?
| | Iodine Radioisotopes | 1 | 2019 | 139 | 0.150 |
Why?
| | Cattle | 3 | 2022 | 987 | 0.150 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 185 | 0.140 |
Why?
| | Clonal Anergy | 2 | 2011 | 52 | 0.140 |
Why?
| | Mice, Inbred DBA | 4 | 2020 | 199 | 0.140 |
Why?
| | Lung Injury | 1 | 2021 | 218 | 0.140 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 291 | 0.140 |
Why?
| | Complement C4b-Binding Protein | 1 | 2017 | 3 | 0.140 |
Why?
| | Tetanus Toxin | 1 | 2017 | 6 | 0.140 |
Why?
| | Protein Binding | 3 | 2019 | 2232 | 0.140 |
Why?
| | Lung Transplantation | 1 | 2021 | 314 | 0.140 |
Why?
| | Ligands | 1 | 2019 | 666 | 0.140 |
Why?
| | Kidney | 3 | 2023 | 1475 | 0.130 |
Why?
| | Vaccines, Synthetic | 1 | 2017 | 127 | 0.130 |
Why?
| | Inflammation Mediators | 1 | 2019 | 511 | 0.130 |
Why?
| | Complement Pathway, Alternative | 2 | 2018 | 122 | 0.120 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 85 | 0.120 |
Why?
| | Models, Molecular | 1 | 2021 | 1598 | 0.120 |
Why?
| | Endothelial Cells | 1 | 2021 | 786 | 0.120 |
Why?
| | Tuberculosis | 1 | 2019 | 281 | 0.120 |
Why?
| | Mycobacterium tuberculosis | 1 | 2019 | 317 | 0.120 |
Why?
| | Down-Regulation | 3 | 2015 | 635 | 0.120 |
Why?
| | Antigens | 2 | 2015 | 356 | 0.120 |
Why?
| | Self Tolerance | 1 | 2015 | 27 | 0.110 |
Why?
| | Immunoglobulin D | 1 | 2015 | 29 | 0.110 |
Why?
| | Phospholipids | 2 | 2015 | 219 | 0.110 |
Why?
| | Myocardial Reperfusion | 1 | 2015 | 51 | 0.110 |
Why?
| | Antibodies, Bispecific | 1 | 2015 | 55 | 0.110 |
Why?
| | Lymphocyte Depletion | 2 | 2013 | 136 | 0.110 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2015 | 135 | 0.110 |
Why?
| | Humans | 20 | 2023 | 138102 | 0.110 |
Why?
| | Peptide Fragments | 1 | 2017 | 691 | 0.100 |
Why?
| | Spinal Cord Injuries | 1 | 2017 | 229 | 0.100 |
Why?
| | Cell Death | 1 | 2015 | 373 | 0.100 |
Why?
| | Complement C1q | 1 | 2013 | 37 | 0.100 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2013 | 23 | 0.100 |
Why?
| | Lymphocyte Count | 2 | 2011 | 150 | 0.100 |
Why?
| | Retinal Pigment Epithelium | 1 | 2013 | 76 | 0.100 |
Why?
| | Genes, RAG-1 | 1 | 2012 | 12 | 0.100 |
Why?
| | Craniocerebral Trauma | 1 | 2014 | 168 | 0.090 |
Why?
| | Head Injuries, Closed | 1 | 2012 | 48 | 0.090 |
Why?
| | Immunosuppressive Agents | 2 | 2021 | 863 | 0.090 |
Why?
| | Transplantation, Homologous | 1 | 2013 | 412 | 0.090 |
Why?
| | Cytokines | 1 | 2019 | 2079 | 0.090 |
Why?
| | Amidines | 1 | 2011 | 14 | 0.090 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2011 | 19 | 0.090 |
Why?
| | Ornithine | 1 | 2011 | 28 | 0.090 |
Why?
| | Peritoneum | 1 | 2011 | 43 | 0.090 |
Why?
| | Mice, Inbred BALB C | 3 | 2023 | 1260 | 0.090 |
Why?
| | Adaptive Immunity | 1 | 2012 | 172 | 0.090 |
Why?
| | Hydrolases | 1 | 2011 | 55 | 0.080 |
Why?
| | Biomarkers | 2 | 2019 | 4111 | 0.080 |
Why?
| | Injections | 1 | 2011 | 187 | 0.080 |
Why?
| | Transgenes | 1 | 2011 | 185 | 0.080 |
Why?
| | Acute Kidney Injury | 1 | 2018 | 803 | 0.080 |
Why?
| | Female | 9 | 2023 | 73648 | 0.080 |
Why?
| | Germinal Center | 3 | 2022 | 63 | 0.080 |
Why?
| | Graft Rejection | 1 | 2013 | 577 | 0.080 |
Why?
| | Peptides, Cyclic | 2 | 2011 | 265 | 0.070 |
Why?
| | Chronic Disease | 1 | 2015 | 1791 | 0.070 |
Why?
| | Heart Transplantation | 1 | 2015 | 694 | 0.070 |
Why?
| | Brain Ischemia | 1 | 2011 | 342 | 0.070 |
Why?
| | Inflammation | 2 | 2016 | 2847 | 0.070 |
Why?
| | Organ Specificity | 3 | 2016 | 307 | 0.070 |
Why?
| | Doxorubicin | 2 | 2023 | 338 | 0.070 |
Why?
| | Enzyme Inhibitors | 1 | 2011 | 847 | 0.070 |
Why?
| | Lymphoid Tissue | 1 | 2007 | 79 | 0.070 |
Why?
| | Dendritic Cells, Follicular | 2 | 2022 | 7 | 0.060 |
Why?
| | Extracellular Space | 1 | 2007 | 119 | 0.060 |
Why?
| | Lymphopenia | 2 | 2007 | 64 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2013 | 701 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2013 | 1322 | 0.060 |
Why?
| | Rats | 1 | 2015 | 5564 | 0.060 |
Why?
| | Homeodomain Proteins | 3 | 2015 | 506 | 0.060 |
Why?
| | Signal Transduction | 2 | 2011 | 5068 | 0.060 |
Why?
| | Cell Line | 3 | 2017 | 2865 | 0.060 |
Why?
| | Male | 12 | 2021 | 67984 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 2 | 2020 | 662 | 0.060 |
Why?
| | Interferon-alpha | 1 | 2006 | 201 | 0.060 |
Why?
| | Amino Acid Sequence | 1 | 2009 | 2159 | 0.060 |
Why?
| | Recombinant Proteins | 2 | 2021 | 1349 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2009 | 2925 | 0.050 |
Why?
| | Stroke | 1 | 2011 | 1133 | 0.050 |
Why?
| | Agammaglobulinemia | 1 | 2002 | 34 | 0.050 |
Why?
| | Adjuvants, Immunologic | 2 | 2017 | 238 | 0.050 |
Why?
| | Brain | 1 | 2014 | 2725 | 0.050 |
Why?
| | T-Lymphocytes | 2 | 2012 | 1983 | 0.040 |
Why?
| | Capsid Proteins | 1 | 2022 | 94 | 0.040 |
Why?
| | In Situ Nick-End Labeling | 2 | 2012 | 124 | 0.040 |
Why?
| | Arthritis, Rheumatoid | 2 | 2011 | 1157 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2009 | 3404 | 0.040 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 112 | 0.040 |
Why?
| | Stem Cells | 1 | 2005 | 598 | 0.040 |
Why?
| | Proteolysis | 1 | 2021 | 176 | 0.040 |
Why?
| | Thymocytes | 1 | 2020 | 35 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 568 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2020 | 107 | 0.040 |
Why?
| | DNA | 1 | 2006 | 1448 | 0.040 |
Why?
| | Antibodies, Neutralizing | 1 | 2022 | 302 | 0.040 |
Why?
| | Molecular Dynamics Simulation | 1 | 2021 | 243 | 0.040 |
Why?
| | Lymphocytes | 1 | 2021 | 392 | 0.040 |
Why?
| | Spleen | 2 | 2013 | 521 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 320 | 0.040 |
Why?
| | Blotting, Western | 2 | 2012 | 1223 | 0.040 |
Why?
| | Aging | 1 | 2009 | 1859 | 0.040 |
Why?
| | Protein Conformation | 1 | 2021 | 944 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2020 | 4160 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2022 | 648 | 0.030 |
Why?
| | Synovial Membrane | 2 | 2011 | 121 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2012 | 1718 | 0.030 |
Why?
| | Apoptosis | 2 | 2020 | 2555 | 0.030 |
Why?
| | Locomotion | 1 | 2017 | 106 | 0.030 |
Why?
| | Models, Animal | 1 | 2017 | 392 | 0.030 |
Why?
| | Time Factors | 3 | 2015 | 6845 | 0.030 |
Why?
| | Genes, Synthetic | 1 | 2015 | 14 | 0.030 |
Why?
| | Transplantation Tolerance | 1 | 2015 | 38 | 0.030 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2014 | 26 | 0.030 |
Why?
| | Albuminuria | 1 | 2015 | 187 | 0.030 |
Why?
| | fas Receptor | 1 | 2014 | 96 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2021 | 3569 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 2016 | 329 | 0.030 |
Why?
| | Complement C3-C5 Convertases | 1 | 2013 | 23 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 407 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 235 | 0.020 |
Why?
| | Surface Plasmon Resonance | 1 | 2013 | 88 | 0.020 |
Why?
| | Oxidants | 1 | 2013 | 112 | 0.020 |
Why?
| | Choroidal Neovascularization | 1 | 2013 | 56 | 0.020 |
Why?
| | Astrocytes | 1 | 2014 | 211 | 0.020 |
Why?
| | Rituximab | 1 | 2013 | 174 | 0.020 |
Why?
| | Microglia | 1 | 2014 | 250 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2013 | 332 | 0.020 |
Why?
| | Protein-Arginine Deiminases | 1 | 2011 | 16 | 0.020 |
Why?
| | Collagen Type II | 1 | 2011 | 54 | 0.020 |
Why?
| | Blood-Brain Barrier | 1 | 2012 | 137 | 0.020 |
Why?
| | Citrulline | 1 | 2011 | 45 | 0.020 |
Why?
| | Myocardium | 1 | 2015 | 900 | 0.020 |
Why?
| | Lymphocyte Subsets | 1 | 2009 | 87 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 413 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2009 | 169 | 0.020 |
Why?
| | Vaccination | 1 | 2017 | 1431 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 854 | 0.020 |
Why?
| | Immune System | 1 | 2009 | 181 | 0.020 |
Why?
| | Species Specificity | 1 | 2009 | 584 | 0.020 |
Why?
| | Binding Sites, Antibody | 1 | 2007 | 41 | 0.020 |
Why?
| | Receptors, HIV | 1 | 2007 | 25 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2009 | 323 | 0.020 |
Why?
| | Antibodies, Blocking | 1 | 2007 | 35 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2730 | 0.020 |
Why?
| | K562 Cells | 1 | 2007 | 93 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2021 | 10832 | 0.020 |
Why?
| | Virion | 1 | 2007 | 113 | 0.020 |
Why?
| | Lupus Vulgaris | 1 | 2006 | 5 | 0.020 |
Why?
| | Antigen-Antibody Reactions | 1 | 2006 | 55 | 0.020 |
Why?
| | Lung | 1 | 2019 | 4065 | 0.020 |
Why?
| | HIV | 1 | 2007 | 246 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2009 | 612 | 0.010 |
Why?
| | Neurons | 1 | 2014 | 1593 | 0.010 |
Why?
| | Fibrinogen | 1 | 2006 | 171 | 0.010 |
Why?
| | Hyaluronan Receptors | 1 | 2005 | 103 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2009 | 452 | 0.010 |
Why?
| | Young Adult | 1 | 2021 | 13329 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2005 | 366 | 0.010 |
Why?
| | Collagen | 1 | 2006 | 454 | 0.010 |
Why?
| | Erythrocyte Transfusion | 1 | 2005 | 197 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2838 | 0.010 |
Why?
| | Leukotriene B4 | 1 | 2002 | 42 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 2002 | 135 | 0.010 |
Why?
| | Up-Regulation | 1 | 2005 | 844 | 0.010 |
Why?
| | Aged | 1 | 2021 | 23995 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 2005 | 883 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2002 | 324 | 0.010 |
Why?
| | Phenotype | 1 | 2009 | 3158 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 2002 | 419 | 0.010 |
Why?
| | Middle Aged | 1 | 2021 | 33509 | 0.010 |
Why?
| | Intestines | 1 | 2002 | 354 | 0.010 |
Why?
| | Adult | 1 | 2021 | 38063 | 0.010 |
Why?
| | HIV Infections | 1 | 2007 | 2945 | 0.010 |
Why?
|
|
Kulik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|